Neu­rol­o­gists pass on Aduhelm again. Most agree with CMS de­ci­sion to lim­it cov­er­age, study finds

A ma­jor­i­ty of neu­rol­o­gists agree with Medicare on the need for more da­ta on Bio­gen and Ei­sai’s Alzheimer’s dis­ease med Aduhelm, de­spite FDA ap­proval. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.